Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives.

Abstract

Uveal melanoma is a rare but aggressive subtype of melanoma. Nearly 50% of patients will develop metastatic disease despite primary enucleation or radiation therapy. There is currently no standard of care therapy for metastatic uveal melanoma, and no therapy that has been shown to prolong overall survival. Uveal melanoma is characterized by activation of signaling pathways including the MAPK pathway and the PI3K/AKT pathway, among others, via mutations in the G-α-proteins GNAQ and GNA11. MEK inhibition with selumetinib has been evaluated as a therapeutic strategy in metastatic uveal melanoma. This review will discuss preclinical and clinical studies evaluating selumetinib in metastatic uveal melanoma, as well as potential future perspectives on MEK inhibition in the management of metastatic uveal melanoma.

• Authors: Kimberly M Komatsubara, Daniel K Manson, Richard D Carvajal
• Journal: Future oncology (London, England) (Future Oncol) Vol. 12 Issue 11 Pg. 1331-44 (Jun 2016) ISSN: 1744-8301 [Electronic] England
• PMID: 27044592 (Publication Type: Journal Article, Review)

Chemical References

• AZD 6244
• Antineoplastic Agents
• Benzimidazoles

Topics

• Animals
• Antineoplastic Agents (therapeutic use)
• Benzimidazoles (therapeutic use)
• Humans
• Melanoma (drug therapy)
• Uveal Neoplasms (drug therapy)